It is almost one in the morning and you have nine tabs open about a treatment you had never heard of a month ago. Somewhere in the house is a person you love who has already tried two or three medications that did not work. You are the one doing the reading, because nobody else will.
Before you open a tenth tab, here is a finding from our own survey. We asked 443 adults in ten Midwest states whose word would really tip them toward trying ketamine or esketamine care. Their own doctor came out far ahead at 74 percent. Where you sit, as a close friend or relative, drew 18 percent. Someone they follow online who served in uniform or as a first responder drew 4 percent, while an ad managed only 2 percent and a podcast host 1.
Read that as the researcher, not a marketer: you are the 18 percent.
The part that stings, and why it helps
Nobody wants to hear that their voice counts for less than a stranger in a white coat, and that is not quite what the number says. It says a recommendation from inside the family carries weight, but one from a clinician carries about four times as much.
So the job you have been doing at one in the morning may be slightly the wrong job. You have been building a case: links, clinic comparisons, the rehearsed conversation where you finally get through. The higher-leverage move is smaller. Get the question in front of a clinician who can answer it, and let that conversation do the convincing you have been trying to do alone.
You are not the closer. You are the one who gets the appointment on the calendar, and that is the harder and more valuable half.
The numbers are final, validated figures.
Where people say they would go
A related question asked who respondents would go to first if they wanted this treatment, and the answers match. Primary care drew 56 percent of first stops; psychiatrists and other mental health clinicians drew 23. Searching online alone drew 12 percent, asking a friend 1, while 5 percent admitted to having no starting point at all.
Two numbers matter for a caregiver. The 56 percent says the front door for most families is an ordinary primary care visit, not a specialty clinic you must hunt down. The 5 percent is everyone who felt lost; if that has been you these past weeks, you have company, and the answer is less exotic than the search results suggest.
You are in the majority, not the margin
Another figure is worth sitting with. Depression, anxiety, or PTSD that resisted ordinary treatment had touched 72 percent of respondents or someone close to them. It was personal for 37 percent and a loved one's struggle for 22 percent, with 13 percent in both camps and 28 percent in neither.
That 22 percent is the caregiver seat, and with the 13 percent carrying it on both sides, it is not a rare position. Treatment-resistant depression gets discussed like an unusual case, but in this sample contact with it was closer to ordinary.
Expect the name to be unfamiliar
Spravato, an approved nasal spray containing esketamine, meant nothing to 73 percent of respondents; another 21 percent knew the word without knowing what it described, and 6 percent knew. Your loved one is probably in one of the first two groups.
Plan around that. Walking in with a product name can land as pressure rather than information. Walking in with a history lands better: what has been tried, for how long, at what dose, and what happened.
What to actually do this week
None of this is medical advice or a promise about how things will go. It is the practical version of what the data points to.
- Put the medication history on paper before the appointment, including drug names, approximate dates, known doses, and the reason each ended. That sheet will carry more weight with the clinician than anything else you bring.
- Ask the primary doctor a question instead of requesting a treatment: this has not responded to standard medication, so what are the next options, and is a psychiatric referral appropriate? Requests get deflected; questions get answered.
- Ask directly whether treatment-resistant depression fits as a working description, since that phrase opens a different tier of options.
- Offer to attend, and ask whether your person wants you in the room or the waiting area. Either answer is fine; being asked matters.
- Handle consent if you want to join follow-up calls and see records. Without it, the clinic legally cannot tell you much.
- Learn the difference between the approved esketamine spray, dosed under watch at certified sites, and at-home ketamine, a far grayer category, and never discuss them as the same thing. Brain Recovery Centers keeps a plain page on its supervised Spravato care that helps with that distinction.
What to let go of
Let go of winning the argument at the kitchen table, and of the idea that you must understand the pharmacology before you may raise it. You do not, and the survey suggests almost nobody does. Let go of urgency as a tactic, too. Pushing harder is the one-in-the-morning instinct, and it tends to backfire. The steadier version is a calendar and a piece of paper.
The honest limits of this
This is market research about how people choose care, not clinical evidence. Nothing in it shows whether a treatment helps any particular person, and it is not medical advice. Whether ketamine or esketamine therapy suits the person you love is a clinician's call, made with their full history, medications, and risks in view.
If the person you look after has spoken of not wanting to be here, or the load on you feels unbearable tonight, 988 takes calls and texts around the clock. Caregivers are welcome on that line, not only people in crisis, and you may use it for yourself.
Methodology
As the publisher, we commissioned this survey and paid its cost. Pollfish ran it as survey 395586438 on its consumer panel, and when fieldwork wrapped on June 23, 2026, the sample stood at 443 people, every one of them 18 to 64 and a resident of one of ten Midwest states. On questions that allowed more than one answer, the totals exceed 100. All figures come from the final, validated panel data.